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Abstract
The paired box genes are a family of nine developmental control genes, which in human beings (PAX) and mice (Pax) encode nuclear
transcription factors. The temporal and spatial expressions of these highly conserved genes are tightly regulated during foetal develop-
ment including organogenesis. PAX/Pax genes are switched off during the terminal differentiation of most structures. Specific mutations
within a number of PAX/Pax genes lead to developmental abnormalities in both human beings and mice. Mutation in PAX3 causes
Waardenburg syndrome, and craniofacial-deafness-hand syndrome. The Splotch phenotype in mouse exhibits defects in neural crest
derivatives such as, pigment cells, sympathetic ganglia and cardiac neural crest-derived structures. The PAX family also plays key roles
in several human malignancies. In particular, PAX3 is involved in rhabdomyosarcoma and tumours of neural crest origin, including
melanoma and neuroblastoma. This review critically evaluates the roles of PAX/Pax in oncogenesis. It especially highlights recent
advances in knowledge of how their genetic alterations directly interfere in the transcriptional networks that regulate cell differentiation,
proliferation, migration and survival and may contribute to oncogenesis.
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Introduction
The paired box (PAX/Pax) transcription factor family encoded by
developmental control genes is characterized by a highly con-
served paired-box DNA-binding domain (PD). This domain was
initially identified in the Drosophila pair-rule segmentation gene
paired (prd). Since that time, PAX/Pax homologues have been dis-
covered in numerous species from nematodes and sea urchins to
human beings [1–3]. At present, nine paired box genes are known
in mice (Pax1 to Pax9) and human beings (PAX1 to PAX9), divided
into four subgroups based on two additional motifs, the presence
or absence of a conserved octapeptide (OP) distal to the PD and a
complete or truncated version of a homeodomain (HD) (Table 1).
The temporal and spatial expressions of PAX genes are tightly reg-
ulated. Expression is primarily observed during embryonal devel-
opment, being switched off during later phases of terminal differ-
entiation of most structures. Specific mutations within a number
of the PAX/Pax genes lead to a range of developmental abnormal-
ities in both human beings and mouse. Several members of 
the PAX family, especially subgroups II (PAX2, PAX5 and PAX8)
and III (PAX3 and PAX7), play key roles in human malignancies,
such as renal tumours, lymphoma, medullary thyroid carcinoma,
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Table 1 Paired box transcription factor family
Subgroup/
PAX gene
Chromosome
location
Structure Expression during devel-
opment 
Syndromes/diseases associated with PAX/
Pax genes
Human Mouse PD OP HD TD Human syn-
dromes/diseases
Mouse knock-out
phenotype
I
1 20p11 2 + +  + Sclerotome, thymus
Skeleton
Klippel–Feil syndrome,
Jarcho–Levin syn-
drome, salivary gland
tumour
Disturbed skeletogenesis
9 14q12-13 12 + +  + Sclerotome, Skeleton,
cranio-facial, teeth, thymus
No thymus, no parathy-
roid glands, no teeth,
craniofacial and limb
defects
Oligodontia, esophageal
carcinoma, Jarcho-Levin
syndrome
II
2 10q25 19 + + Truncated + CNS, kidney, eye, ear,
mammary gland
Renal–coloboma syn-
drome (papillorenal
syndrome), renal cell
carcinoma, Wilms’
tumour, breast cancer,
Kaposi sarcoma
Renal-coloboma syndrome
5 9p13 4 + + Truncated + CNS, B lymphoid, testis Large cell lymphoma,
lymphocytic leukaemia,
medulloblastoma, neu-
roblastoma, astrocy-
toma 
No B-cells, brain defects
8 2q12-14 2 + + Truncated + CNS, kidney, thyroid Thyroid dysplasia, thy-
roid follicular carci-
noma, Wilms’ tumour,
cancer of placenta,
ovarian serous tumours
Hypothyroidism, neural
crest defect
III
3 2q35 1 + + Complete + CNS, NC, muscle Waardenburg syn-
drome, RMS, Ewing’s
sarcoma
Sp, Spr, Spd, Sp1H, Sp2H,
Sp4H
7 1p36.2 4 + + Complete + CNS, NC, muscle RMS, Ewing’s sarcoma,
melanoma, squamous
cell lung carcinoma
Neural crest defect
IV
4 7q32 6 +  Complete + CNS, pancreas Silver–Russell syn-
drome, Wolcott–Rallison
syndrome, diabetes,
insulinoma
No pancreatic‚ , -cells
6 11p13 2 +  Complete + CNS, eye, nose Aniridia, cataract,
glioblastoma multi-
form, anaplastic
glioblastoma, astrocytic
glioma
Small eye, no pancreatic 
-cells, brain defects 
PD, paired-box DNA-binding domain; OP, octapeptide; HD, paired-type homeodomain (absent in subgroup I PAX proteins and truncated to a single
helix in subgroup II PAX proteins); TD, proline–serine–threonine-rich transactivation domain; CNS, central nervous system; NC, neural crest and
RMS, rhabdomyosarcoma. Refer to text for further structural and functional details.
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rhabdomyosarcoma (RMS) and melanoma [4–6]. In this review,
the roles of PAX genes in cancer are critically evaluated, in partic-
ular those of PAX3 and PAX2.
PAX proteins and embryogenesis
PAX proteins can mediate DNA binding or transcriptional activa-
tion through distinct domains. The PD that makes sequence-spe-
cific contacts with DNA is composed of 128 amino acid residues.
Several PAX proteins possess a second DNA-binding domain, the
paired-type HD, which consists of highly conserved 60 amino acid
residues. The HD shows strong homology with similar domains in
other homeobox type gene products. Strong cooperative interac-
tions occur between the PD and HD on DNA binding [7]. However,
the PD can bind to the target DNA independently and with high
affinity. In contrast, an independent binding of isolated HD cannot
be detected. Most PAX proteins also contain an OP motif located
between PD and HD. Deletion of the OP in some PAX/Pax indicates
it has a transcriptional inhibitory activity [8]. The transactivation
domain (TD) is a proline, threonine- and serine-rich region at the
carboxy terminus of PAX that has been shown to mediate tran-
scriptional regulation [4, 9].
PAX proteins have been implicated as regulators of embryoge-
nesis and as crucial factors in maintaining the pluripotency of
stem cell populations and cell-lineage specification during devel-
opment [6, 10, 11]. Mutations of PAX are associated with major
developmental defects. For instance, PAX2 and PAX8 double
mutants show a complete lack of kidney formation [12]. Mutations
in PAX3 and Pax3 cause Waardenburg syndrome and craniofacial-
deafness-hand syndrome in human beings and the Splotch phe-
notype in mice, respectively [13, 14]. Heterozygous mutations in
PAX6/Pax6 result in eye abnormalities (microphthalmia) in human
beings, mice and rats, respectively. Homozygous Pax6-mutant
mice fail to develop eyes and nasal structures, display severe brain
abnormalities and die soon after birth [15]. Key target organs or
tissues of each PAX protein and its role in human diseases, includ-
ing cancer, are presented in Table 1.
PAX genes and cancer
Persistent expression of PAX in partially differentiated tissues is
associated with a block in tissue differentiation and hyperplasia.
PAX are frequently expressed in cancer, and endogenous PAX
gene expression is required for the growth and survival of cancer
cells [16]. Pax1-3, -6 and -8 induce cellular transformation.
Transfection of 3T3 cells with wild-type Pax1, Pax3, Pax6, or Pax8
produced tumours in nude mice within 2 to 6 weeks; Pax2 did so
in 10 days. The tumours were well vascularized and resembled
spindle cell sarcomas, with high and atypical mitotic activity and
infiltration into nerve and muscle tissues, and blood vessels [17].
Several chromosomal translocations involving members of the
subgroups II (PAX5 and PAX8) and III (PAX3 and PAX7) occur in
various human cancers, suggesting altered regulation or
transcriptional activity of PAX gene products promotes cellular
transformation. Alterations in PAX genes of subgroups II and III
are often associated with an unfavourable outcome, and knock-
down of their expression in cancer cells leads to apoptosis. In
contrast, PAX genes in subgroups I are either less often involved
in cancer or their expression is indicative of a more favourable
outcome. So far, PAX1 (subgroup I) has been found by DNA
microarray analysis to be up-regulated only in human salivary
gland tumours [18]. The other member of subgroup I, PAX9, is
expressed in normal epithelium of the adult human oesophagus
and is absent or significantly reduced in the majority of invasive
carcinomas and pre-cancerous epithelial dysplasias [19].
With regard to subgroup IV, overexpression of PAX4 has been
linked to insulinoma and lymphoma. PAX4 is expressed in the
early pancreas but later expression is restricted to -cells and is
absent in mature islets [20]. PAX4 is highly expressed in human
insulinomas [21]. In vitro studies show that PAX4 controls insuli-
noma cell survival through up-regulation of the anti-apoptotic
gene, BCL-XL [22]. Demethylation in the promoter region of
PAX4, leading to its overexpression, has been observed in primary
lymphoma [23]. The forced expression of PAX4 gene in HEK293
and SHSY/610 cell lines enhances cell growth. Thus ectopically
expressed PAX4 may have oncogenic roles in vivo by de-regulat-
ing cell proliferation and survival signals. PAX6 is expressed
throughout the pancreatic bud during embryogenesis but not in
the mature pancreas. The expression of PAX6 occurs in primary
pancreatic adenocarcinomas and cell lines [24]. The overexpres-
sion of Pax6 in transgenic mice promotes ductal and islet cell pro-
liferation and the subsequent development of pancreatic cystic
adenoma [25]. However, PAX6 exerts a tumour suppressor func-
tion that limits the growth of glioblastoma cells. High levels of
PAX6 expression are correlated with improved prognosis in malig-
nant astrocytic gliomas, whereas low levels are associated with an
unfavourable outcome [26]. PAX6 suppresses the invasiveness of
glioblastoma cells by repressing the expression of MMP2 [27].
Methylation and silencing of PAX6 has been observed in breast
cancers [28]. Recently, it was reported that Pax6-transduced
(non-neuronal) Hela cells express neuron-specific genes and
Pax6 expression is a strong signal for induction of cell migration
[29]. Whether PAX6/Pax6 confers positive or negative effects on
cell proliferation and migration would seem to depend on the 
cell type.
PAX3 gene in embryogenesis and cancer
PAX3 is located on chromosome 2q35. Full-length PAX3 consists
of 10 exons encoding a 510 amino acid residue protein. Human
PAX3 protein is 98% identical to the mouse orthologue [30].
Studies in Xenopus show that both Pax3 and Zic1 are independ-
ently required for neural crest (NC) differentiation. The cooperative
functions of Pax3 and Zic1 determine NC cells fate [31]. PAX3
expression is necessary for proliferation and migration of NC cells
and muscle cell precursors in the dorsal dermomyotome. It is also
involved in developmental pathways that lead to melanocytes and
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neurons originating from the NC, and mature skeletal myocytes
from the dorsal dermomyotome. Accordingly, PAX3 is implicated
in the pathogenesis of tumours associated with these tissues,
including RMS, melanoma and neuroblastoma. The following 
section will focus on the functions of PAX3 and the roles of 
its isoforms in myogenesis, melanogenesis, neurogenesis and
related oncogenesis.
PAX3 in myogenesis and RMS
Skeletal muscles are formed from the paraxial mesoderm sur-
rounding the neural tube. Cells of the dermomyotome exhibit
early, restricted patterns in expression of Pax3 and Pax7, and then
develop into skeletal muscles of the trunk and limbs. Pax3 is
involved in induction and migration of myoblast precursors, and
in the expression of the muscle-specific transcription factors,
MyoD, Myf-5 and myogenin (Fig. 1A). However, Pax3 is down-reg-
ulated when muscle tissue begins to differentiate and the muscle-
specific transcription factors are activated [32, 33]. Ectopic
expression of Pax3 prevents the myogenic differentiation of
myoblasts into myotubes, which might involve the cooperation of
Msx1 and Notch genes [34–37]. In chicken embryos, the expres-
sion of Msx1 overlaps with Pax3 in migrating limb muscle precur-
sors and Msx1 antagonizes the myogenic activity of Pax3 [38].
Msx2, another Msx homeobox gene family member, was found to
be an immediate downstream effector of Pax3. Pax3 represses
Msx2 expression in the development of the murine cardiac neural
crest [39]. Pax3 potentiates the migration of hypaxial muscle pre-
cursors by directly modulating the expression of c-Met tyrosine
kinase receptor [40, 41]. Interestingly, in muscle tumours, which
often harbour an activated PAX3, c-MET is up-regulated [42].
Therefore, both muscle development and tumourigenesis involve
regulation of the MET pathway by PAX3. In P19 carcinoma cells,
Wnt3 up-regulates Pax3 expression, which in turn, activates Six1,
Eya2 and Dach2. This is followed by the down-regulation of Pax3
and activation of MyoD and myogenin expression [43, 44]. Thus
evidence supports a role for Pax3 as a controller of a cascade of
transcriptional events that are necessary and sufficient for skeletal
myogenesis. This role deserves greater study from both scientific
and clinical viewpoints. This hypothesis is also supported by
observations that PAX3/Pax3 mutations are associated with limb
muscle hypoplasia in Waardenburg syndrome patients and
Splotch phenotype mice, respectively [33, 45]. PAX3 and PAX7
have similar structures and patterns of expression. Despite this, a
lack of PAX3 expression during embryogenesis may not be com-
pensated for by PAX7 or other genes [46, 47]. On the other hand,
the distinct roles of Pax3 and Pax7 in regenerative myogenesis of
adult mammals suggest that Pax3 may not compensate for Pax7
in postnatal muscle development [48]. However, the function of
Pax7 in specification of postnatal myogenic satellite cells is still
controversial [49, 50]. The interaction between Pax3 and Pax7
needs further clarification.
RMS is the most frequent soft tissue tumour in children under
15 years old. It develops as a consequence of disruption to the
regulation of the growth and differentiation of myogenic precursor
cells. In contrast to normal myogenic cells, RMS tumour cells
remain in cell cycle and usually fail to differentiate completely into
muscle cells.
Embryonal RMS (ERMS) and alveolar RMS (ARMS) are two
major subtypes [51, 52]. A number of molecular genetic lesions
are implicated in the development of RMS. The amplification of
genes, such as PAX3/7-FKHR, MYCN, MDM2 and CDK4, is a char-
acteristic feature of ARMS. Specific chromosomal gains, including
chromosomes 2, 8, 12 and 13, are associated with ERMS. In addi-
tion, the disruption of some genes, for example IGF2, P16, TP53
and of the HGF/c-MET signalling pathway has been implicated in
the progression of RMS [42, 53–55]. Unlike normal muscle, a CpG
island within PAX3 is hypermethylated in the majority of ERMS but
not in most ARMS. This CpG methylation is inversely correlated
with PAX3 expression [51].
Chromosomal translocations are characteristic of ARMS: with
t(2;13)(q35;q14) and t(1:13)(q36;q14) occurring in about 75%
and 25% of sufferers, respectively (Fig. 1B). The translocations
lead to production of two fusion proteins: PAX3-FKHR and PAX7-
FKHR. A microarray study of RMS identified a novel variant
translocation t(2;2)(q35;q23), which generates a fusion protein
composed of PAX3 and the nuclear receptor co-activator, NCOA1
[56]. The PAX3-NCOA1 protein is a transcriptional activator with
similar transactivation properties to PAX3-FKHR. PAX3-FKHR
shows 10–100 times the transactivating and transforming capac-
ity of wild-type PAX3. The Fas death domain-associated protein
(Daxx) represses the transcriptional activity of Pax3 by approxi-
mately 80% but Pax3-FKHR is unresponsive to this repressive
effect [57]. Daxx-mediated repression of Pax3 is inhibited by the
nuclear body associated protein PML [58]. PAX3-FKHR induces
the expression of a large set of genes involved in myogenesis,
such as MyoD1, myogenin and Six1. Other downstream targets
are BCL-XL, FKHR, TGF-, PDGF- receptor, insulin-like growth
factor (IGF)-1 receptor, as well as genes that are not normally tar-
gets of wild-type PAX3 [51, 59]. A comparison of the gene expres-
sion profiles using microarrays revealed an overexpression of
putative PAX3-FKHR target genes, such as DCX, CNR1, in PAX3-
FKHR positive ARMS, relative to that in PAX3-FKHR negative
ERMS [60]. The role(s) of PAX3/7-FKHR in promoting the differ-
ent molecular pathogeneses of ARMS and ERMS remains to be
tested and would surely prove to be a fruitful topic of study.
PAX3-FKHR can induce cellular transformation and prevent
apoptosis [61, 62]. Furthermore, it shows oncogenic effects,
predominantly at relatively low levels although suppression of
growth occurs at higher levels [59]. The two DNA-binding
domains of PAX3-FKHR, that is PD and the HD, are functionally
separate influencing the control of growth suppression and
transformation, respectively. In a landmark study, the mouse
myoblast C2C12 cell line was transfected singly with cDNA for
Pax3, PAX3-FKHR, IGF-II or cotransfected with IGF-II plus Pax3
or with IGF-II plus PAX3-FKHR genes. All transfectants showed
altered morphologies, a lack of differentiation and higher prolif-
eration rates in vitro [63]. Moreover, the subcutaneous injection
of C2C12 transfectants into nude mice produced tumours.
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Tumours derived from IGF-II and PAX3-FKHR cotransfected cells
were composed of undifferentiated cells showing most angio-
genesis, least apoptosis and invaded normal muscle tissues.
Schaaf et al. found that IGF-II is expressed at higher levels in
RMS than in normal muscles [64], suggesting that PAX3 or
PAX3-FKHR interact with IGF-II to play a critical role in RMS
development, which is summarized in Fig. 2. Recently, the abil-
ity of PAX3 and PAX3-FKHR to promote RMS cell survival by
regulating the expression of PTEN or TFAP2B was demonstrated
[65, 66]. The involvement of PAX3 and PAX3-FKHR in RMS
tumourigenesis is likely to be by at least partially altering the
MET, PTEN or AP2 signalling pathways.
PAX3 in melanogenesis and melanoma
Melanocytes are dendritic pigment-producing cells that originate
from non-pigmented precursors of the NC melanoblasts. Several
transcription factors, including PAX3 and microphthalmia-associ-
ated transcription factor (MITF), are involved in this transforma-
tion. Pax3 is required to expand a pool of committed melanoblasts
or restricted progenitor cells early in development, whereas MITF
facilitates melanoblast survival within and immediately after,
migration from the dorsal neural tube [67]. The expression of
Pax3 is probably necessary, but not sufficient, for maintaining
Fig. 1 (A) PAX3 and PAX7 are involved in myogenesis during embryonic development. The ectopic expression of PAX3 prevents terminal myogenic dif-
ferentiation, possibly by regulating Msx1 and Notch signalling. (B) Schematic representation of the chromosomal translocations involving PAX3/PAX7
and FKHR, which are known to result in alveolar rhabdomyosarcoma.
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melanocytes in their differentiated state [68]. PAX3 promotes
melanocyte lineage commitment while simultaneously preventing
their differentiation (Fig. 3) [69]. Furthermore, PAX3 alone or in
synergy with SOX10, activates MITF [70]. Failures in this regula-
tion arising from PAX3 mutations cause the auditory–pigmentary
symptoms in Waardenburg syndrome 1 patients [71].
Melanocytes can develop into cutaneous and ocular
melanoma. Pigmented ocular tumours can also develop from
proliferating cells of the retinal pigment epithelium [72]. The
incidence and mortality of cutaneous melanoma have increased
at annual rates of 2–3% worldwide over the last 30 years, with
the greatest increases seen in elderly men [73]. Melanomas can
clinically progress through four subtypes: benign naevi to dys-
plastic naevi then radial and vertical growth phase melanoma
and finally metastatic melanoma (Fig. 3) [74]. Dysplastic 
naevus has been suggested as the precursor of cutaneous
melanoma.
The transition of melanocytes into clinically characterized
melanoma is associated with changes in the function of numer-
ous genes. Melanoma susceptibility genes are CDKN2A and
CDK4, those for growth factors, such as bFGF, PDGF and EGF,
and for proteins in signalling pathways, especially MAPK, STAT
and Nodal [75–78]. Several transcription factors, such as PAX3,
MITF, SOX10, c-MYC, PTEN, RAS and c-RET, also play roles in
the pathogenesis of melanoma [79]. PAX3 is a key transcription
factor in regulating the expression of a variety of melanocytic
genes [69, 80].
PAX3 is expressed in primary melanomas and melanoma cell
lines but not in the surrounding normal tissues or skin sections.
Transfection of melanoma cells with antisense PAX3 oligonu-
cleotides triggers cell death by inducing apoptosis [81, 82]. The
down-regulation of Pax3 in interleukin-6 receptor/interleukin-6
induced melanoma cells (B16F10.9) is linked to arrested growth
and transdifferentiation to a glial cell phenotype. Pax3 reduction
Fig. 2 A diagrammatic representation sum-
marizing how PAX3 and the chimeric protein,
PAX3-FKHR could promote the development
of rhabdomyosarcoma (ERMS, embryonal
rhabdomyosarcoma and ARMS, alveolar
rhabdomyosarcoma).
Fig. 3 The common origin of melanocytes and nerve cells from the neural crest and the development and progression of normal melanocytes to
metastatic melanoma. The roles of PAX3 in neurogenesis, melanogenesis and melanoma development are proposed.
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also induces a loss of melanogenesis, followed by a sharp
decrease in MITF mRNA and gene promoter activity [83].
Recently, PAX3 was identified as a regulator of the melanoma sus-
ceptibility and progression genes SCF, TGF-, MUC18, RhoC and
TIMP3 using microarray analyses [84, 85]. In quiescent cells, the
retinoblastoma tumour suppressor protein, pRB, in its unphos-
phorylated state, interacts with the transcription factor E2F and
inhibits the transcription of E2F-responsive genes, which are
essential for cell cycle progression. PAX3 interacts strongly 
with pRB [86].
PAX3 in neurogenesis and neuroblastoma
Pax3 is expressed in the developing nervous system during early
neurogenesis (Fig. 3) [87]. The induction of Pax3 in P19 embry-
onal carcinoma stem cells is closely linked to subsequent neu-
ronal differentiation [88]. Koblar et al. found that Pax3 regulates
the generation of sensory neurons from precursors that origi-
nate from the NC [89]. They demonstrated that Pax3 mRNA was
initially expressed in all NC cells but was later restricted to neu-
rons. The addition of FGF2 to the cultures significantly increased
Pax3 mRNA expression in NC cells and resulted in increased
neurogenesis.
Neuroblastoma is the commonest extracranial solid tumour in
childhood. It is a disease of the sympathicoadrenal lineage of the
neural crest, and therefore primary tumours may originate in all
sites of peripheral sympathetic ganglia and paraganglia [90, 91].
Many genetic abnormalities have been implicated in neuroblas-
tomas, including amplification of the N-MYC oncogene [92].
Overexpression of transfected N-MYC induces cellular transfor-
mation. For example, transgenic mice overexpressing N-MYC in
NC-derived tissues frequently develop neuroblastomas. However,
a reduced expression of N-MYC in cultured human neuroblastoma
cell lines decreases proliferation and induces differentiation [93].
Abnormally elevated expression of PAX3 has also been found in
some neuroblastoma cell lines and tumours [94]. Deletion and
mutagenesis experiments have shown that Pax3 contains the
inverted E box sequence CGCGTG (or CACGCG) in the 5 promoter
region, which responds to regulation by N-Myc and c-Myc. Mouse
N-Myc and c-Myc directly activate the Pax3 promoter and the
ectopic expression of N-Myc and c-Myc increases Pax3 expres-
sion [95]. Whether PAX3 initiates pathogenesis of neuroblastoma
or N-MYC induces neuroblastoma by modulating PAX3 expres-
sion, is a question worthy of further investigation.
PAX3 splicing and tumours
The PAX3 isoforms are designated as PAX3a, PAX3b, PAX3c,
PAX3d, PAX3e, PAX3g and PAX3h (Fig. 4) [30, 96, 97]. PAX3a and
PAX3b are encoded by exons 1–4 and lack the HD and the carboxy
terminal TD. PAX3c, d and e contain 8, 9 and 10 exons, respec-
tively, and their isoforms possess intact HD and TD. Both PAX3c
and PAX3d are evolutionarily conserved in human beings and
mice. Intron 8 is retained in PAX3c transcript and translation pro-
ceeds from exon 8 for five codons into intron 8 before reaching a
stop codon. Intron 8 is spliced in PAX3d, and translation proceeds
from exon 8 to exon 9. The predicted amino acid residues of
PAX3c and PAX3d are identical except at the extreme carboxy ter-
mini. In vitro DNA-binding and transactivation studies suggested
that PAX3d is functionally similar to PAX3c [30, 46]. PAX3g and
PAX3h are truncated isoforms of PAX3d and PAX3e, respectively
[97], both lack part of the TD encoded by exon 8.
Alternative transcripts of PAX3 have been identified in a variety
of tissues, including human adult skeletal muscle and mouse
embryos. Pax3g, also named Pax38, occurs in primary mouse
myoblasts [98]. A transient transfection assay demonstrated that
Pax3g was transcriptionally inactive, although its presence effec-
tively inhibited the activity of Pax3d, presumably by competing
with it for Pax3-binding sites. A further alternative splicing occurs
in Pax3 at the intron 2/exon 3 junction and results in the inclusion
Fig. 4 PAX3 isoforms. The diagram illustrates the structure of PAX3 iso-
forms a-h DNA-binding domains: PD, paired domain; HD, homeodomain
and TD, transactivation domain (not to scale). Lower vertical arrows and
numbers indicate the nucleotide position of exon boundaries and the
additional exons 9 and 10 are also indicated.
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or exclusion of a glutamine (Q) residue (Pax3/Q and Pax3/Q–
forms, respectively) in the linker between the amino and carboxy
terminal paired box domains [99]. The Pax3/Q– form has stronger
binding affinity and higher transcriptional activity than the
Pax3/Q but both Q/– forms are co-expressed in equal abun-
dance during multiple developmental stages in mice. A functional
study of PAX3 isoforms in mouse melanocytes in vitro demon-
strated they differ in biological functions [100]. PAX3c, d and h
promote melanocyte proliferation, migration, transformation and
survival. Other isoforms have negative or no discernable effects
on melanocytes.
PAX3 splicing variants show distinct expression profiles in dif-
ferent tumours. Compared to PAX3a, a high proportion of neurob-
lastomas and RMS express PAX3b, although the levels of both are
low. Truncated isoforms of PAX6 act in a dominant negative man-
ner when co-expressed with wild-type PAX6 [101]. Similar results
have been found with PAX4 and PAX5. Thus PAX3a and PAX3b
might interact in a similar way with other PAX3 isoforms to regu-
late their functions.
PAX3d is present in Ewing’s sarcoma, melanoma and ERMS
cell lines but is generally absent in neuroblastoma [46]. PAX3c
and PAX3d are preferentially expressed in melanocytes,
melanoma cell lines and melanoma tissues but only faintly in
testes, muscle, brain and brain tumours and are absent in the
other normal tissues and cancer cell lines [102]. PAX3d is the
main isoform present in ARMS cell lines tested although PAX3c is
expressed strongly in half of them (our unpublished data). With
regard to ERMS cell lines, PAX3c and PAX3d are expressed at low-
to-moderate levels [46].
Thus the published literature suggests that PAX3 isoforms may
have significant roles in the development and progression of
tumours of NC origin, specifically, PAX3c and PAX3d in
melanomas and PAX3g and PAX3h in neuroblastomas [46, 94, 97,
100, 102]. PAX3a and PAX3b may function by regulating the
transactivation properties of the other isoforms, as indeed, do the
truncated isoforms of PAX4, PAX5 and PAX6. The precise roles of
these PAX3 spliced variants in normal developmental processes
and in oncogenesis remain to be elucidated, and surely warrants
an extended series of investigations.
PAX2 in tumourigenesis
A comprehensive immunohistochemical study involving 54 cancer
cell lines and 406 primary tumour tissues representing eight com-
mon tumour types, found 90% of cancer cell lines and 25% of
tumours of brain, breast, colon, lung, ovary, prostate, lymphoma
and melanoma are PAX2 positive (Fig. 5). PAX2 RNA interference
induces apoptosis in tumour cells [16]. It was demonstrated that
inhibition of PAX2 expression in prostate cancer cells results in
cell death [103]. Similarly, transfection of antisense PAX2 into
Kaposi sarcoma cells results in reduced cell motility, invasiveness
and cell death [104] indicating that the endogenous expression of
PAX2 is needed for their growth and survival.
PAX2, apart from being crucial to the development of the
kidney, eye and mammary gland, is involved in paediatric
nephroblastoma or Wilms’ tumour. This arises from the primi-
tive metanephric blastema. Wilms’ tumour is frequently associ-
ated with precursor lesions, known as nephrogenic rests that
are the foci of normal embryonal cells persisting into postnatal
life. These may regress, remain dormant, develop into benign
adenomatous structures or progress to Wilms’ tumour [105].
Most cases of Wilms’ tumour are sporadic, but 5–10% are
hereditary. The latter are thought to result from a germ cell
mutation, followed by loss of heterozygosity in a single somatic
cell [106]. Germline and somatic mutations and deletions affect
the Wilms’ tumour suppressor gene, WT1, which is a major
genetic disposing factor in children with Wilms’ tumour. Both
PAX2 and WT1 are normally expressed in tissues undergoing
mesenchyme to epithelial transition. During renal development,
PAX2 and WT1 regulate the expression of each other [107].
WT1 is a negative regulator of PAX2. As the level of WT1
increases, that of PAX2 decreases. High levels of WT1 are first
seen in the proximal region of the S-shaped body, the glomeru-
lar region, where PAX2 expression first declines [108]. The
addition of WT1 to cells with a chloramphenicol acetyl trans-
ferase reporter gene under the control of Pax2 promoter
sequences showed a five-fold reduction in its transcription
[109]. Pax2 can transactivate WT1 and inhibition of Pax2 has
been shown to repress WT1 expression and block nephron dif-
ferentiation [110].
Renal cell carcinoma (RCC) is thought to arise from proximal
tubules in kidney. It often accompanies Von Hippel Lindau (VHL)
syndrome, which is the result of mutations in or deletion of the
VHL tumour suppressor gene. Over 70% of cell lines derived from
RCCs with deletions/mutations of VHL express PAX2 [111].
Indeed, PAX2 is expressed in all renal tumour subtypes, except
© 2008 The Authors
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Fig. 5 Immunohistochemistry is used to screen PAX2 expression in eight
common tumour types including tumours of brain, breast, colon, lung,
ovary, prostate, lymphoma and melanoma. Percentages of human
tumours expressing PAX2 are shown (adapted from [16]).
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transitional cell carcinomas, with papillary RCC expressing the
highest level [112]. Moreover, the extent of PAX2 expression is
correlated with proliferation index and is significantly higher in
patients with metastatic disease.
PAX2 has an anti-apoptotic function in embryonic renal cells
[113]. The inhibition of PAX2 expression in RCC cell lines triggers
growth inhibition and cell death [111]. An increased in PAX2
expression protects cells against high NaCl concentration-
induced apoptosis [114]. The mechanism of PAX2-mediated pro-
tection from cell death is unknown. The mesenchyme of dysplastic
kidneys fails to express the anti-apoptosis gene, BCL-2.
Consequently increased apoptosis is seen in the mesenchyme
which reduces precursor cell survival. In contrast, BCL-2 is
expressed in the dysplastic epithelia [108]. This is ectopic
expression, because ureteric bud derivatives do not normally
express BCL-2, therefore, little or no apoptosis occurs in the dys-
plastic epithelium, enhancing cell proliferation. Because
enhanced expression of PAX3 or PAX3/FKHR stimulates tran-
scription of BCL-XL [115], PAX2 might also play a role regulating
the expression of BCL-2.
PAX5 in tumourigenesis
The chromosomal rearrangement t(9;14)(p13;q32), which
results in the fusion of PAX5 to genes for immunoglobulin
heavy chain, has been reported in a subset of non-Hodgkin’s
lymphomas (NHL) [116]. PAX5 expression occurs in various
types of benign and malignant tumours including B-cell NHL,
Hodgkin lymphomas, Merkel cell carcinoma, small cell carci-
noma, neuroendocrine carcinomas and medulloblastomas [117,
118]. PAX5 is the most frequent site of somatic mutations in
acute lymphoblastic leukaemia [119]. Mutations of p53 are
associated with astrocytomas and glioblastomas. The expres-
sion of PAX5 in astrocytomas is inversely proportional to the
expression of p53, and PAX5 can bind to the p53 promoter,
repressing its activity [120]. PAX5 expression is also identified
in N-type neuroblastoma cells (a malignant subset), but is
absent in S-type cells (a benign subset). The forced expression
of PAX5 in S-type cells has been shown to confer N-type char-
acteristics such as increased rate of proliferation and the ability
to form colonies in soft agar [121]. Recently, it was confirmed
that PAX5 is expressed in poorly differentiated neuroendocrine
tumours but never in well-differentiated classic carcinoid
tumours [122]. However, loss of Pax5 in mature B cells can ini-
tiate lymphoma development in mice despite their advanced dif-
ferentiation [123]. This implies that PAX5/Pax5 has cell type
specific effects on cell differentiation. PAX5 transcription is
enhanced by STAT5 in the early stages of B cell development.
Indeed, a STAT-binding motif has been shown to occur in the
PAX5 promoter [124]. Constitutive activation of STAT5 is asso-
ciated strongly with tumourigenesis [125]. The expression of
dominant-negative Pax5 in murine lymphomas and PAX5 knock-
down in human lymphoma negatively affects cell expansion
[126]. Hence PAX5 may contribute to oncogenesis through the
STAT signalling pathway and/or by the direct inhibition of p53
expression.
PAX8 in tumourigenesis
PAX8 is expressed in most non-invasive urothelial neoplasia but
not in normal adult urothelial epithelium [127]. It is highly
expressed in epithelial ovarian cancer but expression appears
absent in the precursor ovarian surface epithelia of healthy indi-
viduals [128]. The translocation, t(2;3)(q13; p25) results in the
fusion of PAX8 and peroxisome proliferator-activated receptor
gamma (PPARgamma) genes. The production of the PAX8-
PPARgamma fusion protein contributes to neoplasia by acting
as a dominant-negative inhibitor of wild-type PPARgamma
[129]. The occurrence of the PAX8-PPARgamma is thought to
be restricted to follicular tumours (adenomas and carcinomas)
of the thyroid. A subset of the follicular variant of papillary thy-
roid carcinoma harbours the PAX8-PARgamma translocation,
which is significantly associated with multi-focality and vascu-
lar invasion [130]. Foukakis et al. demonstrated that the Ras
effector NORE1A, a putative tumour suppressor, is suppressed
in follicular thyroid carcinomas with a PAX8-PPARgamma
fusion [131]. An in vitro study has shown that PAX8-
PPARgamma stimulates thyroid cell viability but inhibits thy-
roid-specific gene expression [132]. Thus it appears possible
that the fusion protein may contribute to the malignant transfor-
mation of thyroid follicular cells by modulating the Ras sig-
nalling pathway.
PAX and the treatment of cancer
PAX proteins may be useful tools in the diagnosis of cancers. For
example, PAX2 immunostaining has been used to identify nephro-
genic adenoma [133]. This staining has been recommended as a
method to distinguish between metastatic ovarian serous papillary
carcinoma and primary breast carcinoma [134]. PAX5 immuno-
histochemistry is employed in the diagnosis and sub-classification
of lymphomas [135].
Genetic alterations to members of the PAX family directly
interfere in transcriptional networks leading to oncogenesis by
regulating tumour cell survival, proliferation and migration [16,
22, 23, 65, 81, 114]. Thus some of the PAX genes are potential
targets for gene-based cancer therapy. Also, gene-specific thera-
pies, such as antisense oligonucleotides or RNA interference-
based treatments have progressed to clinical trials although these
types of treatment have potential problems [136, 137]. However,
the in vitro transfection of tumour cells with appropriate PAX
gene antisense oligonucleotide or RNA interference molecules
induce cell apoptosis or reduce cell proliferation or migration [16,
81, 82, 104, 111, 126].
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PAX fusion proteins, for example PAX3-FKHR, PAX7-FKHR,
PAX8-PPARgamma, have critical roles in malignant transformation.
Recently, Broeke et al. identified a PAX-FKHR fusion protein
breakpoint epitope in ARMS that induced a human cytotoxic
T-lymphocyte line to kill ARMS cells [138]. Thus, PAX fusion
proteins are potential targets of immunotherapy-based treat-
ments for some malignancies. PAX3d is a melanocyte/
melanoma-specific immunogenic antigen capable of inducing
IgG antibodies [102]. Hence the PAX3d isoform may be a use-
ful target for the development of immunotherapy in patients
with melanoma. It is apparent that much work is still required
to elucidate the role(s) of PAX/Pax in normal and disease cells.
However, the benefits to patients of such studies are likely to
be considerable.
Summary
In summary, PAX/Pax transcription factors control organ develop-
ment and tissue differentiation during embryogenesis. They are
involved in regulating cell differentiation, proliferation, migration
and the survival of different cell types through transactivation of
target genes. PAX genes clearly have pivotal roles in the oncoge-
nesis of several human tumours. The use of microarray investiga-
tions has been of enormous value in unravelling the mechanisms
of oncogenesis associated with PAX genes [18, 56, 60, 64, 66, 84,
85, 129]. The vast increases in knowledge of PAX-related activities
provided by such studies are being exploited to identify potential
new targets for cancer treatment.
© 2008 The Authors
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